Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis.

Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H.

J Invest Dermatol. 2007 Jun;127(6):1419-29. Epub 2007 Feb 1.

2.

Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.

Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG.

Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17414-9. Epub 2006 Nov 6.

3.

A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone.

Harvey AJ, Baell JB, Toovey N, Homerick D, Wulff H.

J Med Chem. 2006 Feb 23;49(4):1433-41.

PMID:
16480279
4.

Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain.

Mouhat S, Teodorescu G, Homerick D, Visan V, Wulff H, Wu Y, Grissmer S, Darbon H, De Waard M, Sabatier JM.

Mol Pharmacol. 2006 Jan;69(1):354-62. Epub 2005 Oct 18.

PMID:
16234482
5.

Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.

Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H.

Mol Pharmacol. 2005 Nov;68(5):1254-70. Epub 2005 Aug 11.

PMID:
16099841

Supplemental Content

Loading ...
Support Center